一次性骨髓腔输液器的自主研发及其在临床实践中的应用探索  

Independent Research and Development of Disposable Bone Marrow Infusion Set and Exploration of Its Application in Clinical Practice

作　　者：周全 于新海 ZHOU Quan;YU Xin-hai(Shandong Weigao Group Medical Polymer Products Co.,Ltd.,Shandong Weihai 264209)

机构地区：[1]山东威高集团医用高分子制品股份有限公司,山东威海264209

出　　处：《中国医疗器械信息》2025年第5期50-52,共3页China Medical Device Information

摘　　要：目的:探讨一次性骨髓腔输液器的自主研发及其在临床实践中的应用探索。方法:选取2022年6月~2024年6月本院收治的86例急危重患者作为研究对象。随机将其分为观察组及对照组,各43例,对照组给予常规输液器治疗,观察组给予一次性骨髓腔输液器治疗。比较两组患者临床指标及不良反应发生情况。结果:观察组收缩压、心率、操作成功时间及保留时间均显著低于对照组(t=6.539、5.830、15.922、18.805,P<0.05)。观察组患者总不良率(11.63%)显著低于对照组(χ^(2)=5.472,32.56%)(P<0.05)。结论:一次性骨髓腔输液器在临床实践中能够改善临床指标,提高安全性及有效性。Objective:To explore the independent development of disposable bone marrow infusion sets and their application in clinical practice.Methods:86 critically ill patients admitted to our hospital from June 2022 to June 2024 were selected as the research subjects.Randomly divide them into an observation group and a control group,with 43 cases in each group.The control group is treated with conventional infusion sets,while the observation group is treated with disposable bone marrow cavity infusion sets.Compare the clinical indicators and incidence of adverse reactions between two groups of patients.Results:The systolic blood pressure,heart rate,successful operation time,and retention time of the observation group were significantly lower than those of the control group(t=6.539,5.830,15.922,18.805,P<0.05).The total adverse rate of patients in the observation group(11.63%)was significantly lower than that of the control group(χ^(2)=5.472,32.56%)(P<0.05).Conclusion:Disposable bone marrow infusion sets can improve clinical indicators,enhance safety and effectiveness in clinical practice.

关 键 词：一次性骨髓腔输液器 自主研发 临床实践 设计 不良反应 

分 类 号：TH789[机械工程—仪器科学与技术]